thesi updat amerisourc post modestli better anticip
underli core growth ex lot nois msd unfortun
pharmedium remain materi headach seem
clear near-term solut may prefer see asset dispos
less ideal given would materi less
paid year ago didnt understand valu time frankli
doesnt mean give away asset bc near term headach
said guid came see cushion
remain share count tax side could help off-set oi
weak share think expect ep
guid come rear view
may come back specul potenti take-out given proxi
chang less convinc probabl chang
prior press report specul potenti transact materi
would also acknowledg market put low chanc
consolid time view remain given wba
stake need accret cost restructur obvious
rush pursu transact clearli may option
strateg furthermor given alreadi quarter
busi premium like sub typic chang
control roll forecast come modestli pt goe
certainti improv underli fundament rx distributor
broadli view compel current valuat
risk reward still remain favor despit today move
reiter outperform rate tweak pt
model/pt updat lower forecast given haircut
pharmedium profit expect also tweak tax rate
help cushion declin estim move lower given
base effect reset well conserv view
esrx contribut given recent news pt move
ep line level consist teen discount
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
conduct review pharmedium busi
could make invest chang even sale
believ result consent decre
still testing/etc facil product littl
lower normal
timelin resumpt full level product
facil
guidanc remov contribut memphi facil
opex grow msd
contempl origin guidanc
higher end rang brazil
consolid off-set hd smith synergi
world courier mwi improv consult
op incom grow hsd
ep like rel flat yoy
normal tax rate
pharmedium headwind smaller decemb
item reduct defer comp liabil
chang brand/gener price come line
brand activ later year
contract subject inflat
benefit manufactur consolid
also benefit commerci servic
sever year see trend
adj op incom ex-pharmedium hd smith/brazil would
msd
tax reform discret tax benefit
revenu flat quarter impact agenc switch
companion anim busi lsd growth ex-ag
normal prior qs
littl product delay cattl movement
catch dec-feb
expand relationship mar
alway focus work togeth creat
year relationship banfield mar
still lower contribut lash yoy
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti resumpt independ price war result materi margin degrad
signific profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin
result overal compress increment soft pharmedium growth lessen inflat continu challeng
relat revamp qc process polit threat chang rx price methodolog gross net intens scrutini
opioid curtail distribut profit execut challeng onboard hd smith asset potenti leakag key
independ custom transit period inabl transit specialti contract long term new econom
allow fair payment differenti servic
laboratori corp america
articl articl
time dissemin januari
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
